BridgeBio announced positive top‑line results from a global Phase III study of oral infigratinib in children with achondroplasia, meeting the trial’s primary endpoint for accelerated annualized height velocity. The study reported statistically significant increases in growth rate versus placebo and recorded a tolerability profile that the company characterized as manageable. BridgeBio plans regulatory engagements after the readout and highlighted the oral mechanism as a distinct option alongside injectable competitors. The result expands late‑stage momentum across rare‑disease programs and sets up a potential filing that would pit an oral FGFR3 inhibitor against marketed and pending therapies for dwarfism.